CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Natera inc   (NTRA)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

NTRA's Revenue Growth by Quarter and Year

Natera Inc 's Revenue results by quarter and year




NTRA Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 311.11 217.25 173.03 112.38
III Quarter September 268.31 210.64 158.12 98.14
II Quarter June 261.40 198.20 142.03 86.47
I Quarter March 241.76 194.13 152.32 94.01
FY   1,082.58 820.22 625.50 391.00



NTRA Revenue fourth quarter 2023 Y/Y Growth Comment
Natera inc reported Revenue rise of 43.2% year on year in the fourth quarter 2023, to $ 311.11 millions, this is lower than Natera Inc 's recent average Revenue rise of 58.69%.

Looking into fourth quarter 2023 results within Medical Laboratories industry 6 other companies have achieved higher Revenue growth. While Natera Inc ' s Revenue jump of 43.2% ranks overall at the positon no. 910 in the fourth quarter 2023.


NTRA Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
IV Quarter December 43.2 % 25.56 % 53.97 % 35.01 %
III Quarter September 27.38 % 33.22 % 61.12 % 25.97 %
II Quarter June 31.89 % 39.55 % 64.25 % 16.29 %
I Quarter March 24.54 % 27.45 % 62.03 % 40.69 %
FY   31.99 % 31.13 % 59.97 % 29.33 %

Financial Statements
Natera Inc 's fourth quarter 2023 Revenue $ 311.11 millions NTRA's Income Statement
Natera Inc 's fourth quarter 2022 Revenue $ 217.25 millions Quarterly NTRA's Income Statement
New: More NTRA's historic Revenue Growth >>


NTRA Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
IV Quarter December 15.95 % 3.14 % 9.43 % 14.51 %
III Quarter September 2.64 % 6.28 % 11.33 % 13.5 %
II Quarter June 8.12 % 2.1 % -6.76 % -8.02 %
I Quarter March 11.28 % 12.19 % 35.54 % 12.94 %
FY (Year on Year)   31.99 % 31.13 % 59.97 % 29.33 %


Explore NTRA Customer Growth by Product and Service >> Back to NTRA Growth rate Comparisons >>


Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #7
Healthcare Sector #138
Overall #910

Revenue Y/Y Growth Statistics
High Average Low
410.42 % 58.69 % -36.26 %
(Mar 31 2017)   (Dec 31 2017)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #7
Healthcare Sector #138
Overall #910
Revenue Y/Y Growth Statistics
High Average Low
410.42 % 58.69 % -36.26 %
(Mar 31 2017)   (Dec 31 2017)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Natera Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
202.82 % 10.12 % -71.26 %
(Dec 31 2016)  


NTRA's IV. Quarter Q/Q Revenue Comment
Natera inc achieved in the IV. Quarter 2023 above company average sequential Revenue jump of 15.95%, to $ 311.11 millions, from $268.31 millions in the third quarter.
Medical Laboratories company is undergoing a remarkable growth, not only reporting better then regular increase, but also improving rate.

Within Medical Laboratories industry Natera inc achieved highest sequential Revenue growth. While Natera Inc 's Revenue growth quarter on quarter, overall rank is 320.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #0
Healthcare Sector #48
Overall #320
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #0
Healthcare Sector #48
Overall #320
Revenue Q/Q Growth Statistics
High Average Low
202.82 % 10.12 % -71.26 %
(Dec 31 2016)  


NTRA's IV. Quarter Q/Q Revenue Comment
Natera inc achieved in the IV. Quarter 2023 above company average sequential Revenue jump of 15.95%, to $ 311.11 millions, from $268.31 millions in the third quarter.
Natera Inc is impressively improving, not only recording better then normal growth, and additionally accelerating rate, Kevin Young, market consultant said.

Within Medical Laboratories industry Natera inc achieved highest sequential Revenue growth. While Natera Inc 's Revenue growth quarter on quarter, overall rank is 320.


Natera Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 1,082.57 $ 988.72 $ 931.05 $ 867.85 $ 820.22
Y / Y Revenue Growth (TTM) 31.99 % 27.41 % 28.69 % 30.05 % 31.13 %
Year on Year Revenue Growth Overall Ranking # 210 # 415 # 387 # 297 # 109
Seqeuential Revenue Change (TTM) 9.49 % 6.19 % 7.28 % 5.81 % 5.7 %
Seq. Revenue Growth (TTM) Overall Ranking # 910 # 1580 # 1357 # 1451 # 1526

New: More NTRA's historic Revenue Growth >>



Cumulative Revenue growth Comment
Although Natera Inc 's Annual Revenue growth year on year were below company's average 58.69% , Revenue announced in the Dec 31 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 31.99% year on year, from 27.41% in Sep 30 2023.

In the Healthcare sector 47 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 210, from total ranking in previous quarter at 415.

Revenue TTM Q/Q Growth Statistics
High Average Low
410.42 %
58.69 %
-36.26 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 7
Healthcare Sector # 48
Overall # 210

Revenue TTM Y/Y Growth Statistics
High Average Low
410.42 %
58.69 %
-36.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 138
S&P 500 # 910
Cumulative Revenue growth Comment
Although Natera Inc 's Annual Revenue growth year on year were below company's average 58.69% , Revenue announced in the Dec 31 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 31.99% year on year, from 27.41% in Sep 30 2023.

In the Healthcare sector 47 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 210, from total ranking in previous quarter at 415.

Revenue TTM Q/Q Growth Statistics
High Average Low
410.42 %
58.69 %
-36.26 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 7
Healthcare Sector # 48
Overall # 210

Revenue TTM Y/Y Growth Statistics
High Average Low
410.42 %
58.69 %
-36.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 138
S&P 500 # 910




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NTRA's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for NTRA's Competitors
Revenue Growth for Natera Inc 's Suppliers
Revenue Growth for NTRA's Customers

You may also want to know
NTRA's Annual Growth Rates NTRA's Profitability Ratios NTRA's Asset Turnover Ratio NTRA's Dividend Growth
NTRA's Roe NTRA's Valuation Ratios NTRA's Financial Strength Ratios NTRA's Dividend Payout Ratio
NTRA's Roa NTRA's Inventory Turnover Ratio NTRA's Growth Rates NTRA's Dividend Comparisons



Companies with similar Revenue jump for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Abeona Therapeutics Inc 74.00%$ 74.005 millions
Esperion Therapeutics inc 71.38%$ 71.378 millions
Electrocore Inc 71.37%$ 71.367 millions
Cvrx inc70.81%$ 70.805 millions
Mainz Biomed N v 69.00%$ 68.998 millions
Elite Pharmaceuticals Inc 68.64%$ 68.637 millions
Nephros Inc 67.97%$ 67.971 millions
Bicycle Therapeutics Plc67.38%$ 67.378 millions
Axim Biotechnologies Inc 66.79%$ 66.790 millions
Cyclo Therapeutics Inc 66.70%$ 66.699 millions
Beigene ltd 66.67%$ 66.666 millions
Agios Pharmaceuticals Inc 64.80%$ 64.803 millions
Lifemd Inc 64.28%$ 64.276 millions
Lumos Pharma Inc 61.33%$ 61.328 millions
Inspiremd Inc 58.66%$ 58.664 millions
Aurinia Pharmaceuticals Inc 58.59%$ 58.590 millions
Bioxcel Therapeutics Inc 57.98%$ 57.983 millions
Tela Bio Inc 53.10%$ 53.102 millions
Theralink Technologies Inc 51.82%$ 51.820 millions
Intra cellular Therapies Inc 50.34%$ 50.336 millions
Adma Biologics Inc 49.43%$ 49.427 millions
Insmed Inc48.27%$ 48.273 millions
Hims and Hers Health Inc 48.15%$ 48.151 millions
Armata Pharmaceuticals Inc 45.39%$ 45.385 millions
G1 Therapeutics Inc 45.10%$ 45.102 millions
Genfit S a 43.70%$ 43.702 millions
Natera inc 43.20%$ 43.200 millions
Shockwave Medical Inc 41.36%$ 41.361 millions
Eiger Biopharmaceuticals Inc 41.06%$ 41.061 millions
Revance Therapeutics Inc 39.82%$ 39.819 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com